FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1999822150> ?p ?o ?g. }

• W1999822150 endingPage "71" @default.
• W1999822150 startingPage "69" @default.
• W1999822150 abstract "Background: The efficacy of chemotherapy protocols for the treatment of high-grade non-Hodgkin’s lymphoma (NHL) has not improved significantly during the last decade. Treatment results in patients presenting with high-grade NHL are not satisfactory. At present, etoposide remains the only drug that may add to the efficacy of the CHOP regimen. Hemopoietic growth factors like G-CSF allow a dose intensification of effective chemotherapy regimens by shortening the time of neutro-penia and allowing earlier application of subsequent cycles. We have initiated a phase I/II trial of CHOP + etoposide (CHOEP) applied in 14-day intervals with G-CSF support to test the feasibility of this regimen before starting a trial comparing its efficacy with the more conventional regimens. Patients and Methods: Patients with high-grade NHL according to the Kiel classification were treated with the CHOEP-14 regimen, consisting of cyclophosphamide (750 mg/m2 i.v., day 1), doxorubicin (50 mg/m2, day 1), vincristine (2 mg i.v., day 1), etoposide (100 mg/m2, days 1-3) and prednisolone (100 mg p.o., days 1-5). G-CSF, 300 μg (up to 75 kg body weight) or 480 μg was applied s.c. (days 4-13). Cycles were repeated on day 15 and patients received 6 cycles followed by irradiation of bulky disease with 36 Gy. Results: To date, 30 patients with high-grade NHL (median age 55 years, range 25-79 years) have been treated for a total of 159 evaluable chemotherapy cycles. 24 patients have finished 6 cycles each, and 20 patients are evaluable for response. Application of the following cycle was on day 15 in 146/159 cycles, and delay in 16 cycles (duration between 1 and 13 days) was not caused by ncutro-penia in any patient. Leucopenia < 1,000/mm3 occurred in 18/159 cycles, but never lasted longer than 4 days. White blood cell counts recovered completely by day 14 in all cycles. Toxicity was tolerable and never exceeded WHO grade 3. A complete remission (CR) was observed in 17/20 patients, a partial remission (PR) in 2/20 patients before radiation therapy. One patient died due to disease progression (cerebral involvement). Conclusion: Dose intensification of the standard CHOP regimen by addition of etoposide and implementation of 14-day cycles with growth factor support is possible without undue increase in treatment toxicity. A randomized multicenter phase III trial has been initiated to test whether this significant increment in dose intensity translates into increased remission rates and/or longer remission durations." @default.
• W1999822150 created "2016-06-24" @default.
• W1999822150 creator A5003056562 @default.
• W1999822150 creator A5014979722 @default.
• W1999822150 creator A5042788885 @default.
• W1999822150 creator A5064558275 @default.
• W1999822150 creator A5071228709 @default.
• W1999822150 creator A5080151991 @default.
• W1999822150 creator A5090490279 @default.
• W1999822150 date "1994-01-01" @default.
• W1999822150 modified "2023-10-16" @default.
• W1999822150 title "Intensification of the CHOEP Regimen for High-Grade Non- Hodgkin’s Lymphoma by G-CSF: Feasibility of a 14-Day Regimen" @default.
• W1999822150 doi "https://doi.org/10.1159/000218385" @default.
• W1999822150 hasPublicationYear "1994" @default.
• W1999822150 type Work @default.
• W1999822150 sameAs 1999822150 @default.
• W1999822150 citedByCount "14" @default.
• W1999822150 countsByYear W19998221502013 @default.
• W1999822150 crossrefType "journal-article" @default.
• W1999822150 hasAuthorship W1999822150A5003056562 @default.
• W1999822150 hasAuthorship W1999822150A5014979722 @default.
• W1999822150 hasAuthorship W1999822150A5042788885 @default.
• W1999822150 hasAuthorship W1999822150A5064558275 @default.
• W1999822150 hasAuthorship W1999822150A5071228709 @default.
• W1999822150 hasAuthorship W1999822150A5080151991 @default.
• W1999822150 hasAuthorship W1999822150A5090490279 @default.
• W1999822150 hasConcept C126322002 @default.
• W1999822150 hasConcept C141071460 @default.
• W1999822150 hasConcept C2776694085 @default.
• W1999822150 hasConcept C2776715498 @default.
• W1999822150 hasConcept C2776755627 @default.
• W1999822150 hasConcept C2778119113 @default.
• W1999822150 hasConcept C2778336483 @default.
• W1999822150 hasConcept C2778476748 @default.
• W1999822150 hasConcept C2779338263 @default.
• W1999822150 hasConcept C2779429289 @default.
• W1999822150 hasConcept C2779725641 @default.
• W1999822150 hasConcept C2781413609 @default.
• W1999822150 hasConcept C71924100 @default.
• W1999822150 hasConcept C90924648 @default.
• W1999822150 hasConceptScore W1999822150C126322002 @default.
• W1999822150 hasConceptScore W1999822150C141071460 @default.
• W1999822150 hasConceptScore W1999822150C2776694085 @default.
• W1999822150 hasConceptScore W1999822150C2776715498 @default.
• W1999822150 hasConceptScore W1999822150C2776755627 @default.
• W1999822150 hasConceptScore W1999822150C2778119113 @default.
• W1999822150 hasConceptScore W1999822150C2778336483 @default.
• W1999822150 hasConceptScore W1999822150C2778476748 @default.
• W1999822150 hasConceptScore W1999822150C2779338263 @default.
• W1999822150 hasConceptScore W1999822150C2779429289 @default.
• W1999822150 hasConceptScore W1999822150C2779725641 @default.
• W1999822150 hasConceptScore W1999822150C2781413609 @default.
• W1999822150 hasConceptScore W1999822150C71924100 @default.
• W1999822150 hasConceptScore W1999822150C90924648 @default.
• W1999822150 hasIssue "1" @default.
• W1999822150 hasLocation W19998221501 @default.
• W1999822150 hasOpenAccess W1999822150 @default.
• W1999822150 hasPrimaryLocation W19998221501 @default.
• W1999822150 hasRelatedWork W1973686872 @default.
• W1999822150 hasRelatedWork W2077242620 @default.
• W1999822150 hasRelatedWork W2121694206 @default.
• W1999822150 hasRelatedWork W2158035792 @default.
• W1999822150 hasRelatedWork W2183352065 @default.
• W1999822150 hasRelatedWork W2368204729 @default.
• W1999822150 hasRelatedWork W2403217642 @default.
• W1999822150 hasRelatedWork W2435139026 @default.
• W1999822150 hasRelatedWork W247605849 @default.
• W1999822150 hasRelatedWork W2519696495 @default.
• W1999822150 hasVolume "17" @default.
• W1999822150 isParatext "false" @default.
• W1999822150 isRetracted "false" @default.
• W1999822150 magId "1999822150" @default.
• W1999822150 workType "article" @default.